Literature DB >> 19859628

Lung and renal transplantation.

Patrícia Caetano Mota1, Ana Paula Vaz, Inês Castro Ferreira, Manuela Bustorff, Carla Damas.   

Abstract

UNLABELLED: Renal transplantation is the most common type of solid organ transplantation and kidney transplant recipients are susceptible to pulmonary complications of immunosuppressive therapy, which are a diagnostic and therapeutic challenge. AIM: To evaluate patients admitted to the Renal Transplant Unit (RTU) of Hospital de S. João with respiratory disease. SUBJECT AND METHODS: We performed a retrospective study of all patients admitted to RTU with respiratory disease during a period of 12 months.
RESULTS: Thirty-six patients were included. Mean age 55.2 (+/-13.4) years; 61.1% male. Immunosuppressive agents most frequently used were prednisolone and mycophenolate mofetil associated with ciclosporin (38.9%) or tacrolimus (22.2%) or rapamycin (13.9%). Thirty-one patients (86.1%) presented infectious respiratory disease. In this group the main diagnoses were 23 (74.2%) pneumonias, 5 (16.1%) opportunistic infections, 2 (6.5%) tracheobronchitis, and 1 case (3.2%) of lung abscesses. Microbiological agent was identified in 7 cases (22.6%). Five patients (13.9%) presented rapamycin-induced lung disease. Fibreoptic bronchoscopy was performed in 15 patients (41.7%), diagnostic in 10 cases (66.7%). Mean hospital stay was 17.1 (+/-18.5) days and no related death was observed.
CONCLUSION: Respiratory infections were the main complications in these patients. Drug-induced lung disease implies recognition of its features and a rigorous monitoring of drug serum levels. A more invasive diagnostic approach was determinant in the choice of an early and more specific therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19859628     DOI: 10.1016/s2173-5115(09)70169-1

Source DB:  PubMed          Journal:  Rev Port Pneumol        ISSN: 0873-2159


  1 in total

1.  Risk factors for lung diseases after renal transplantation.

Authors:  Ventsislava P Pencheva; Daniela S Petrova; Diyan K Genov; Ognian B Georgiev
Journal:  J Res Med Sci       Date:  2015-12       Impact factor: 1.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.